Table 1. Novel therapeutic approaches... | American Society of Hematology

Table 1.

Novel therapeutic approaches targeting tumor angiogenesis and tumor cell growth

Agents	Malignancy	Development status
Drugs that block activators of angiogenesis
Anti-VEGF antibody	MDS	Phase I/II
	MM, CML-BP, NHL	Phase II
VEGF-trap	Solid tumors and NHL	Phase I
PTK787/ZK222584	MM	Phase I
	AML, AMM, CML-BP	Phase I/II
	MDS	Phase II
GW786034	Advanced solid tumors	Phase I
Drugs that directly inhibit endothelial cells
Thalidomide	Large B-cell lymphoma; CLL or small lymphocytic lymphoma	Phase II
	MM, primary systemic amyloidosis	Phase II/III
CC-5013 (thalidomide analog)	Solid tumors and/or lymphomas	Phase I
	MDS, AL amyloidosis	Phase II
	MM	Phase II/III
2-ME	MM	Phase I
LY317615 (PKC inhibitor)	DLB-CL	Phase II
Drugs that inhibit endothelial cell—specific integrin/survival signaling
EMD121974 (cilengitide)	Solid tumors and lymphomas	Phase I
	AML	Phase II

Agents	Malignancy	Development status
Drugs that block activators of angiogenesis
Anti-VEGF antibody	MDS	Phase I/II
	MM, CML-BP, NHL	Phase II
VEGF-trap	Solid tumors and NHL	Phase I
PTK787/ZK222584	MM	Phase I
	AML, AMM, CML-BP	Phase I/II
	MDS	Phase II
GW786034	Advanced solid tumors	Phase I
Drugs that directly inhibit endothelial cells
Thalidomide	Large B-cell lymphoma; CLL or small lymphocytic lymphoma	Phase II
	MM, primary systemic amyloidosis	Phase II/III
CC-5013 (thalidomide analog)	Solid tumors and/or lymphomas	Phase I
	MDS, AL amyloidosis	Phase II
	MM	Phase II/III
2-ME	MM	Phase I
LY317615 (PKC inhibitor)	DLB-CL	Phase II
Drugs that inhibit endothelial cell—specific integrin/survival signaling
EMD121974 (cilengitide)	Solid tumors and lymphomas	Phase I
	AML	Phase II

AMM indicates agnogenic myeloid metalplasia; CLL, chronic lymphatic leukemia; and AL, primary systemic amyloidosis.